In addition, because increased activity of JAK/STAT and PI3K/Akt/mTOR signaling pathways was found in CALR-mutated cells, it would be possible to study the response of cells with mutated CALR to drugs (e.g., ruxolitinib and anagrelide) that are currently used in the treatment of MPN (here, we used specific inhibitors that are still only at the preclinical stage but effective against targets in the tested signaling pathways). The gene discussed is PIK3CG; the disease is myeloproliferative neoplasm.